Do bisphosphonates treat CRPS?
Bisphosphonates are bone drugs that 11 randomized trials have tested for complex regional pain syndrome. A 2026 meta-analysis in Annals of Internal Medicine found they may reduce pain by about 10 points on a 100-point scale between four weeks and three months, with low certainty. Neridronate, the most studied bisphosphonate in CRPS, is not approved in the United States.

What are bisphosphonates, and why are they tried for CRPS?
Bisphosphonates are a class of drugs that act on bone. The 2022 practical guidelines in Pain Medicine state that bisphosphonates "have immune-modulatory properties and modulate bone metabolism." Some people with CRPS develop bone thinning in the affected limb, which the guidelines call osteopenia.
The 2022 practical guidelines report a hypothesis that bisphosphonates may work for CRPS marked by bone loss, a subset that bone density testing or a three-phase bone scan might identify. The guidelines add: "To date, this hypothesis remains unproven." The bisphosphonates tested in CRPS trials are alendronate, clodronate, neridronate, pamidronate and zoledronate.
What did the Varenna 2013 neridronate trial find?
The Varenna 2013 trial found that neridronate reduced pain about twice as much as placebo in early CRPS. Varenna and colleagues randomized 82 patients with CRPS type I of the hand or foot in a multicenter trial. Each received four intravenous infusions over 10 days, either 100 mg of neridronate or placebo.
Pain on a 100 mm scale fell by 46.5 mm in the neridronate group and by 22.6 mm in the placebo group. The authors described the patients as having acute CRPS type I and concluded that the infusions were "associated with clinically relevant and persistent benefits." The abstract also describes bisphosphonates as "the treatment of choice," a conclusion that later, larger trials did not support.
What happened in the larger United States neridronate trials?
Two Phase 3 neridronate trials that included United States sites were stopped early for futility. Grunenthal sponsored both, registered as NCT03530345 and NCT03560986, and both began in May 2018. Each enrolled adults with CRPS for two years or less. The registry records state that a planned interim analysis of pooled data "indicated futility (neridronate unlikely to be superior to placebo) and both studies were stopped."
The posted results differ between the two trials. In NCT03530345, pain at week 12 on a 0 to 10 scale fell 1.23 points with neridronate (28 participants) and 0.16 with placebo (29 participants). In NCT03560986, pain fell 1.28 points with neridronate (48 participants) and 1.71 with placebo (51 participants). The difference favored neridronate in the first trial (p = 0.011) and was not significant in the second (p = 0.25). An earlier Grunenthal trial, NCT02402530, enrolled 459 people and has no results posted on the registry.
What does the 2026 meta-analysis of bisphosphonates conclude?
The 2026 meta-analysis concludes that bisphosphonates may reduce CRPS pain in the short term and that the benefit is small and uncertain. Ferraro and colleagues, writing in Annals of Internal Medicine, pooled 11 randomized trials with 754 participants, 97 percent of whom had CRPS type I. Five trials tested neridronate.
Between four weeks and three months, bisphosphonates reduced pain by a mean of 10.0 points on a 0 to 100 scale, rated low certainty. The authors found "little to no difference" at four weeks or less and at three to six months, and called the evidence beyond six months "very uncertain." Bisphosphonates probably increased the risk of adverse events, with a risk ratio of 1.1.
How do the bisphosphonate studies in CRPS compare?
The bisphosphonate studies in CRPS range from one trial of 82 patients to a pooled analysis of 754 participants.
| Study | What it covered | Result |
|---|---|---|
| Varenna 2013, Rheumatology | 82 patients with acute CRPS type I; neridronate or placebo | Pain fell 46.5 mm with neridronate and 22.6 mm with placebo on a 100 mm scale |
| Chevreau 2017, Joint Bone Spine | Meta-analysis of 4 trials, 181 patients | Large short-term pain effect; more adverse events with bisphosphonates |
| Grunenthal trials NCT03530345 and NCT03560986 | 57 and 99 participants; neridronate or placebo | Stopped in 2019 after a pooled interim analysis indicated futility |
| Ferraro 2023, Cochrane overview | Systematic reviews of CRPS treatments | Low-certainty evidence that bisphosphonates may reduce pain |
| Ferraro 2026, Annals of Internal Medicine | Meta-analysis of 11 trials, 754 participants | Pain reduced by 10.0 points of 100 between four weeks and three months, low certainty |
Why did earlier reviews of bisphosphonates look stronger?
Earlier reviews of bisphosphonates rested on four small trials. A 2017 meta-analysis by Chevreau and colleagues pooled those four trials, with 181 patients in all, and reported a large short-term reduction in pain, a standardized mean difference of 2.6 in favor of bisphosphonates. The 2023 Cochrane overview by Ferraro and colleagues used the same four trials and rated the finding low certainty.
The 2026 meta-analysis pooled 11 trials, five of them of neridronate, and found a smaller benefit: 10.0 points on a 100-point scale. The 2026 authors list "high heterogeneity," meaning the trials disagreed with one another, as a limitation.
What do the guidelines say about bisphosphonates for CRPS?
The two main guidelines take different positions on bisphosphonates. The Royal College of Physicians' 2018 guideline states that pamidronate, as a single 60 mg intravenous dose, "should be considered for suitable patients with CRPS less than 6 months in duration as a one-off treatment."
The 2022 practical guidelines are more cautious. They note that several small trials reported benefit and that "two recent large pharma-sponsored trials were either not reported or were reported as negative." They conclude that, "given the occurrence of rare serious side effects," randomized trials are required to confirm a benefit in selected subtypes of CRPS. The 2026 meta-analysis observes that clinical guidelines recommend bisphosphonates "despite limited evidence of efficacy."
Is neridronate available in the United States?
Neridronate is not approved for sale in the United States. The 2026 meta-analysis in Annals of Internal Medicine describes neridronate and clodronate as "non-U.S.-approved formulations." The National Institute of Neurological Disorders and Stroke explains that medicines for CRPS are used "off label," which means they are approved for other conditions. Clinical trials, such as the CRPS-RISE trial described on this page, are where neridronate is being given for CRPS in the United States.
What is the Phase 3 neridronate trial recruiting in California?
The trial is called CRPS-RISE and is registered on ClinicalTrials.gov as NCT07210515. Ambros Therapeutics sponsors it. The registry describes a randomized, triple-blind, placebo-controlled Phase 3 trial with a planned enrollment of 270 adults. Participants receive 100 mg of neridronate or placebo as a two-hour infusion on days 1, 4, 7 and 10, and the main outcome is the change in pain intensity at week 12.
The trial started on April 14, 2026, and the registry estimates that collection of the main outcome data will finish in December 2027. On the date this page was checked, the registry listed recruiting sites in La Jolla, Napa, Pasadena, Santa Monica and Tustin. The CRPS clinical trial finder shows the current status. A listing is not a recommendation to enroll.
Who can join the CRPS-RISE neridronate trial?
The CRPS-RISE trial enrolls a narrow group: adults with early, warm CRPS type I in one limb. The registry record requires a diagnosis under the Budapest clinical criteria, and symptoms that began six months or less before randomization. The limb must be swollen and show at least two of three warm-type features: obvious redness, a temperature at least 1 degree Celsius above the other limb, or moderate to severe swelling. A three-phase bone scan must show increased uptake in the affected limb.
The record excludes people with CRPS type II, people whose CRPS had no known triggering event, and people who had ketamine within six months or an intravenous bisphosphonate within twelve months. It also excludes people with severely impaired kidney function, low blood calcium, vitamin D deficiency or an unhealed tooth extraction site. Study staff decide eligibility.
What side effects have bisphosphonate trials in CRPS reported?
Bisphosphonate trials in CRPS reported more side effects with the drug than with placebo. In the 2017 meta-analysis by Chevreau and colleagues, 35.5 percent of patients on bisphosphonates had an adverse event, compared with 16.4 percent on placebo, and none was serious. The 2026 meta-analysis found, with moderate certainty, that bisphosphonates probably increase the risk of adverse events.
The registry results for the stopped Grunenthal trials list serious adverse events through week 26. In one trial they occurred in 2 of 28 neridronate participants and 0 of 29 placebo participants. In the other they occurred in 2 of 48 and 3 of 51. The 2022 practical guidelines refer to "rare serious side effects" of bisphosphonates without listing them. A prescribing physician is the source for the risks in an individual case.
Common questions
Sources
Every source below was opened and read for this page. The date is when it was last checked.
- Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome: A Systematic Review and Meta-analysisStudy · Annals of Internal Medicine (Ferraro et al.), 2026 · checked
- Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled studyStudy · Rheumatology (Varenna et al.), 2013 · checked
- Bisphosphonates for treatment of Complex Regional Pain Syndrome type 1: A systematic literature review and meta-analysis of randomized controlled trials versus placeboStudy · Joint Bone Spine (Chevreau et al.), 2017 · checked
- Interventions for treating pain and disability in adults with complex regional pain syndrome: an overview of systematic reviewsStudy · Cochrane Database of Systematic Reviews (Ferraro et al.), 2023 · checked
- Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1, CRPS-RISE (NCT07210515)Study · ClinicalTrials.gov (Ambros Therapeutics, Inc.) · checked
- Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1 (NCT07857733)Study · ClinicalTrials.gov (Ambros Therapeutics, Inc.) · checked
- Efficacy and Safety of Intravenous Neridronic Acid in CRPS (NCT03530345), with posted resultsStudy · ClinicalTrials.gov (Grunenthal GmbH) · checked
- Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (NCT03560986), with posted resultsStudy · ClinicalTrials.gov (Grunenthal GmbH) · checked
- Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I (NCT02402530)Study · ClinicalTrials.gov (Grunenthal GmbH) · checked
- CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-I (NCT02504008)Study · ClinicalTrials.gov (Axsome Therapeutics, Inc.) · checked
- Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th EditionClinical guideline · Pain Medicine (Harden et al.), 2022 · checked
- Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care, 2nd editionClinical guideline · Royal College of Physicians, 2018 · checked
- Complex Regional Pain SyndromeGovernment agency · National Institute of Neurological Disorders and Stroke · checked
- ClinicalTrials.gov study registry and APIDataset · U.S. National Library of Medicine · checked

CRPS treatment
CRPS clinical trials
Tests used for CRPS
CRPS clinical trial finder